TGFB1 and pulmonary fibrosis: Researchers have shown in a bleomycin pulmonary fibrosis mouse model, that one of the mechanisms of action of the drug pirfenidone is the suppression of the overactive TGF-β1/Smad2/3 signaling pathways in IPF [57].